These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 22722403)

  • 1. BET domain co-regulators in obesity, inflammation and cancer.
    Belkina AC; Denis GV
    Nat Rev Cancer; 2012 Jun; 12(7):465-77. PubMed ID: 22722403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. You bet-cha: a novel family of transcriptional regulators.
    Florence B; Faller DV
    Front Biosci; 2001 Aug; 6():D1008-18. PubMed ID: 11487468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanism for epigenetic control of DNA replication.
    Sansam CG; Pietrzak K; Majchrzycka B; Kerlin MA; Chen J; Rankin S; Sansam CL
    Genes Dev; 2018 Feb; 32(3-4):224-229. PubMed ID: 29483155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration.
    Gupta SS; Maetzig T; Maertens GN; Sharif A; Rothe M; Weidner-Glunde M; Galla M; Schambach A; Cherepanov P; Schulz TF
    J Virol; 2013 Dec; 87(23):12721-36. PubMed ID: 24049186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.
    Nicholas DA; Andrieu G; Strissel KJ; Nikolajczyk BS; Denis GV
    Cell Mol Life Sci; 2017 Jan; 74(2):231-243. PubMed ID: 27491296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET Bromodomain Proteins as Cancer Therapeutic Targets.
    Shu S; Polyak K
    Cold Spring Harb Symp Quant Biol; 2016; 81():123-129. PubMed ID: 28062533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
    Tang Y; Gholamin S; Schubert S; Willardson MI; Lee A; Bandopadhayay P; Bergthold G; Masoud S; Nguyen B; Vue N; Balansay B; Yu F; Oh S; Woo P; Chen S; Ponnuswami A; Monje M; Atwood SX; Whitson RJ; Mitra S; Cheshier SH; Qi J; Beroukhim R; Tang JY; Wechsler-Reya R; Oro AE; Link BA; Bradner JE; Cho YJ
    Nat Med; 2014 Jul; 20(7):732-40. PubMed ID: 24973920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
    Padmanabhan B; Mathur S; Manjula R; Tripathi S
    J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.
    Denis GV
    Discov Med; 2010 Dec; 10(55):489-99. PubMed ID: 21189220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
    Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
    Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
    Shi J; Vakoc CR
    Mol Cell; 2014 Jun; 54(5):728-36. PubMed ID: 24905006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes.
    Wang F; Deeney JT; Denis GV
    Vitam Horm; 2013; 91():49-75. PubMed ID: 23374712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
    Suarez-Alvarez B; Morgado-Pascual JL; Rayego-Mateos S; Rodriguez RM; Rodrigues-Diez R; Cannata-Ortiz P; Sanz AB; Egido J; Tharaux PL; Ortiz A; Lopez-Larrea C; Ruiz-Ortega M
    J Am Soc Nephrol; 2017 Feb; 28(2):504-519. PubMed ID: 27436852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.